[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20051998L - Torke prosess - Google Patents

Torke prosess

Info

Publication number
NO20051998L
NO20051998L NO20051998A NO20051998A NO20051998L NO 20051998 L NO20051998 L NO 20051998L NO 20051998 A NO20051998 A NO 20051998A NO 20051998 A NO20051998 A NO 20051998A NO 20051998 L NO20051998 L NO 20051998L
Authority
NO
Norway
Prior art keywords
preservative sample
preservative
viscous liquid
sample
dry process
Prior art date
Application number
NO20051998A
Other languages
English (en)
Other versions
NO20051998D0 (no
NO342741B1 (no
Inventor
Yves Mayeresse
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32234471&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20051998(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0225532A external-priority patent/GB0225532D0/en
Priority claimed from GB0225543A external-priority patent/GB0225543D0/en
Priority claimed from GBGB0225520.6A external-priority patent/GB0225520D0/en
Priority claimed from GB0317380A external-priority patent/GB0317380D0/en
Priority claimed from GB0317381A external-priority patent/GB0317381D0/en
Priority claimed from GB0317371A external-priority patent/GB0317371D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of NO20051998D0 publication Critical patent/NO20051998D0/no
Publication of NO20051998L publication Critical patent/NO20051998L/no
Publication of NO342741B1 publication Critical patent/NO342741B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår en fremgangsmåte for å tørke biologiske og andre ustabile prøver slik at de kan konserveres som en svært viskøs væske. Fremgangsmåten omfatter trinnene med å fremstille en konserveringsprøve ved å oppløse/suspendere et aktivt agens i en løsning av et stabiliserende agens, utsette konserveringsprøven for slike temperatur og trykkbetingelser at konserveringsprøven taper løsningsmiddel ved evaporasjon uten frysing eller bobling for å danne et skum og fjerne løsningsmiddel til konserveringsprøven tørker og danner en svært viskøs væske.
NO20051998A 2002-11-01 2005-04-25 Fremgangsmåte for konservering av et aktivt agens, svært viskøs væske, immunogen sammensetning eller vaksine, fremgangsmåte for fremstilling av en vaksine samt kit. NO342741B1 (no)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0225532A GB0225532D0 (en) 2002-11-01 2002-11-01 Drying process
GB0225543A GB0225543D0 (en) 2002-11-01 2002-11-01 Immunogenic composition
GBGB0225520.6A GB0225520D0 (en) 2002-11-01 2002-11-01 Drying process
GB0317380A GB0317380D0 (en) 2003-07-24 2003-07-24 Drying method
GB0317381A GB0317381D0 (en) 2003-07-24 2003-07-24 Drying method
GB0317371A GB0317371D0 (en) 2003-07-24 2003-07-24 Immunogenic composition
PCT/EP2003/012191 WO2004039417A2 (en) 2002-11-01 2003-10-30 Drying process

Publications (3)

Publication Number Publication Date
NO20051998D0 NO20051998D0 (no) 2005-04-25
NO20051998L true NO20051998L (no) 2005-06-24
NO342741B1 NO342741B1 (no) 2018-08-06

Family

ID=32234471

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20052010A NO20052010L (no) 2002-11-01 2005-04-25 Immunogen sammensetning
NO20051998A NO342741B1 (no) 2002-11-01 2005-04-25 Fremgangsmåte for konservering av et aktivt agens, svært viskøs væske, immunogen sammensetning eller vaksine, fremgangsmåte for fremstilling av en vaksine samt kit.
NO20180874A NO344759B1 (no) 2002-11-01 2018-06-21 Fremgangsmåte for konservering av et aktivt agens.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20052010A NO20052010L (no) 2002-11-01 2005-04-25 Immunogen sammensetning

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20180874A NO344759B1 (no) 2002-11-01 2018-06-21 Fremgangsmåte for konservering av et aktivt agens.

Country Status (28)

Country Link
US (3) US8409587B2 (no)
EP (3) EP1575612B1 (no)
JP (2) JP2006504801A (no)
KR (2) KR101130948B1 (no)
AR (2) AR041881A1 (no)
AT (1) ATE352316T1 (no)
AU (2) AU2003287980B2 (no)
BR (1) BR0315767A (no)
CA (2) CA2503946C (no)
CY (2) CY1119504T1 (no)
DE (1) DE60311526T2 (no)
DK (2) DK2395073T3 (no)
ES (3) ES2280809T3 (no)
HK (1) HK1085380A1 (no)
HU (1) HUE034801T2 (no)
IL (2) IL168052A (no)
IS (2) IS7806A (no)
LT (2) LT2395073T (no)
MA (2) MA27551A1 (no)
MX (3) MXPA05004675A (no)
MY (2) MY145693A (no)
NO (3) NO20052010L (no)
NZ (2) NZ539613A (no)
PL (2) PL215237B1 (no)
PT (2) PT2395073T (no)
SI (2) SI2395073T1 (no)
TW (2) TWI332843B (no)
WO (2) WO2004039417A2 (no)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI332843B (en) 2002-11-01 2010-11-11 Glaxosmithkline Biolog Sa Immunogenic composition
US20080176209A1 (en) * 2004-04-08 2008-07-24 Biomatrica, Inc. Integration of sample storage and sample management for life science
SG151298A1 (en) * 2004-04-08 2009-04-30 Biomatrica Inc Integration of sample storage and sample management for life science
US20060099567A1 (en) * 2004-04-08 2006-05-11 Biomatrica, Inc. Integration of sample storage and sample management for life science
GB0409795D0 (en) * 2004-04-30 2004-06-09 Glaxosmithkline Biolog Sa Drying method
TWI398272B (zh) * 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
MX2007016237A (es) 2005-06-27 2008-03-07 Glaxosmithkline Biolog Sa Composicion inmunogenica.
EP1973406B1 (en) * 2005-12-28 2014-03-12 Advanced Bionutrition Corporation A delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
MX2009002560A (es) * 2006-09-07 2009-03-20 Glaxosmithkline Biolog Sa Vacuna.
US8460726B2 (en) * 2006-12-18 2013-06-11 Advanced Bionutrition Corporation Dry food product containing live probiotic
AU2008248640A1 (en) 2007-05-02 2008-11-13 Glaxosmithkline Biologicals S.A. Vaccine
KR101557169B1 (ko) * 2007-05-18 2015-10-02 메디뮨 엘엘씨 냉동 건조 발포체에 의한 생활성 물질의 보존
GB0711683D0 (en) * 2007-06-16 2007-07-25 Enigma Diagnostics Ltd Compositions
JP2010529850A (ja) * 2007-06-16 2010-09-02 エニグマ ディアグノスティックス リミテッド 組成物
EP2182922A4 (en) * 2007-07-26 2010-07-28 Sanofi Pasteur Ltd ANTIGEN-ADJUVANS COMPOSITIONS AND METHOD
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
CA2986751A1 (en) 2009-03-27 2010-09-30 Intervet International B.V. Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
US20120135017A1 (en) 2009-05-26 2012-05-31 Moti Harel Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making
EP2475393A4 (en) * 2009-09-14 2013-08-21 Vu Truong-Le FORMULATION FOR THE ROOM TEMPERATURE STABILIZATION OF A WEAKED LIVING BACTERIAL VACCINE
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
BR112012018839B1 (pt) 2010-01-28 2020-04-14 Advanced Bionutrition Corp composição vítrea seca compreendendo um material bioativo
FR2960781B1 (fr) * 2010-06-07 2013-11-22 Sanofi Pasteur Preparation d'un vaccin oral sec stabilise, compose d'un virus vivant attenue
CA2806734A1 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
EP2598660B1 (en) 2010-07-26 2017-03-15 Biomatrica, INC. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
CN104147605A (zh) 2010-08-13 2014-11-19 高级生物营养公司 用于生物材料的干的贮存稳定用组合物及其制备方法
WO2012028315A1 (en) 2010-09-02 2012-03-08 Sanofi Pasteur Sa A stabilizer for the preparation of a dry polio injectable vaccine composition
AU2011336413B2 (en) 2010-12-02 2015-01-22 Oncolytics Biotech Inc. Liquid viral formulations
TW201233803A (en) 2010-12-02 2012-08-16 Oncolytics Biotech Inc Lyophilized viral formulations
US8512679B2 (en) 2011-03-04 2013-08-20 Elwha Llc Glassy compositions
JP2014516924A (ja) * 2011-04-07 2014-07-17 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 粘度が低減された処方物
CA2832560A1 (en) * 2011-04-07 2012-10-18 Glaxosmithkline Llc Formulations with reduced viscosity
CA2777431A1 (en) 2011-05-20 2012-11-20 Nitto Denko Corporation Pharmaceutical composition and method for producing the same
PE20141413A1 (es) 2011-10-25 2014-10-25 Onclave Therapeutics Ltd Formulaciones de anticuerpo y metodos
WO2014100755A2 (en) 2012-12-20 2014-06-26 Biomatrica, Inc. Formulations and methods for stabilizing pcr reagents
US20160206728A1 (en) * 2013-10-03 2016-07-21 Nitto Denko Corporation Dried influenza vaccine preparation and method of producing the same
JP6469698B2 (ja) * 2013-12-19 2019-02-13 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． ビロソーム製剤の改良
US9902764B2 (en) 2014-02-11 2018-02-27 Massachusetts Institute Of Technology Full spectrum anti-dengue antibody
JP6661554B2 (ja) 2014-06-10 2020-03-11 バイオマトリカ，インク． 周囲温度における血小板の安定化
WO2016012385A1 (en) * 2014-07-21 2016-01-28 Sanofi Pasteur Vaccine composition comprising ipv and cyclodextrins
ES2809482T3 (es) 2015-06-30 2021-03-04 Nestle Sa Composición adecuada para proteger microorganismos
DK3328215T3 (da) 2015-07-29 2021-09-13 Advanced Bionutrition Corp Stabilt tørre probiotiske sammensætninger til særlige kostanvendelser
US10758606B2 (en) * 2015-09-04 2020-09-01 Inventprise, Llc VLP stabilized vaccine compositions
KR102589056B1 (ko) 2015-12-08 2023-10-12 바이오매트리카 인코포레이티드 적혈구 침강 속도의 감소
CN109890413B (zh) 2016-09-02 2024-04-16 赛诺菲巴斯德股份有限公司 脑膜炎奈瑟氏菌疫苗
KR20200144120A (ko) * 2018-04-16 2020-12-28 메르크 파텐트 게엠베하 열 안정성을 개선하기 위한 단백질 제제에 대한 첨가제
WO2020066991A1 (ja) * 2018-09-28 2020-04-02 株式会社大塚製薬工場 アカルボース又はスタキオースを含む哺乳動物細胞保存用液
EP3897710A1 (en) 2018-12-20 2021-10-27 Intervet International B.V. Prime-boost vaccination regimen

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US509893A (en) * 1893-12-05 William griesser
DE1157734B (de) * 1961-08-16 1963-11-21 Behringwerke Ag Verfahren zur Herstellung von haltbaren, oral zu verabreichenden Poliomyelitisvirus-Praeparaten
US3767790A (en) * 1972-02-11 1973-10-23 Nat Patent Dev Corp Microorganisms
US3929132A (en) * 1973-04-10 1975-12-30 Alza Corp Osmotic dispenser
EP0027888B1 (en) 1979-09-21 1986-04-16 Hitachi, Ltd. Semiconductor switch
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
GB8323094D0 (en) * 1983-08-26 1983-09-28 Franks F Preservation of cells
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
DE3682047D1 (de) 1985-07-09 1991-11-21 Quadrant Bioresources Ltd Beschuetzung von proteinen und aehnlichem.
GB8604983D0 (en) * 1986-02-28 1986-04-09 Biocompatibles Ltd Protein preservation
GB8715238D0 (en) 1987-06-29 1987-08-05 Quadrant Bioresources Ltd Food process
GB8801338D0 (en) 1988-01-21 1988-02-17 Quadrant Bioresources Ltd Preservation of viruses
DE3819530A1 (de) * 1988-06-08 1989-12-21 Westphal Geb Jauch Christel Dr Verfahren, traeger und testsatz fuer die kultivierung und mikroskopische untersuchung von zellen
HUT58804A (en) 1988-12-16 1992-03-30 James Cleland Paton Process for producing pneumolysine mutants and pneumococcus vaccines
ZA907737B (en) * 1989-09-29 1991-07-31 Nisshin Oil Mills Ltd Stable immunogen composition for oral administration
JPH03161441A (ja) 1989-11-20 1991-07-11 Senjiyu Seiyaku Kk メイラード反応阻害剤
ATE242784T1 (de) 1990-07-16 2003-06-15 Univ North Carolina Mit der familie der hämolysin-toxine verwandte antigene eisen-ubnterdrückende proteine des n. meningitis
DE69133334T2 (de) 1990-08-23 2004-05-13 University Of North Carolina At Chapel Hill Transferrin bindende proteine aus neisseria-gonorrhoeae und neisseria-meningitidis
US5912336A (en) 1990-08-23 1999-06-15 University Of North Carolina At Chapel Hill Isolated nucleic acid molecules encoding transferrin binding proteins from Neisseria gonorrhoeae and Neisseria meningitidis
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
FR2682041B1 (fr) 1991-10-03 1994-01-14 Pasteur Merieux Serums Vaccins Vaccin contre les infections a neisseria meningitidis.
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
JP3917172B2 (ja) 1992-02-11 2007-05-23 ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン 二重担体の免疫原性構成体
DE69334197T2 (de) 1992-03-02 2008-12-11 Novartis Vaccines And Diagnostics S.R.L. Helicobacter pylori Cytotoxin verwendbar in Impfstoffe und Diagnostik
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
PT835663E (pt) 1992-05-23 2010-01-04 Glaxosmithkline Biolog Sa Vacinas combinadas compreendendo o antigénio de superfície da hepatite b e outros antigénios
FR2692592B1 (fr) 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
DK0594950T3 (da) 1992-10-27 1999-09-13 American Cyanamid Co Pædiatrisk kombinationsvaccine med forbedret immunogenicitet af hver vaccinekomponent
WO1994026304A1 (en) 1993-05-18 1994-11-24 Ohio State Research Foundation Otitis media vaccine
CA2196415A1 (en) * 1994-08-09 1996-02-22 Katsuhiko Ooyama Peroral immunogen composition and process for producing the same
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6265567B1 (en) 1995-04-07 2001-07-24 University Of North Carolina At Chapel Hill Isolated FrpB nucleic acid molecule
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
PL184823B1 (pl) * 1995-06-07 2002-12-31 Quadrant Holdings Cambridge Preparat do przechowywania substancji biologicznie aktywnych oraz sposób wytwarzania preparatu do przechowywania substancji biologicznie aktywnych
EA199800046A1 (ru) 1995-06-07 1998-06-25 Байокем Вэксинс Инк. Полипептид, последовательность днк, вакцинная композиция (варианты), антитело или его фрагмент, вакцина, применения указанных полипептида, последовательности днк и антитела или его фрагмента
IL122431A0 (en) 1995-06-07 1998-06-15 Smithkline Beecham Biolog Combined vaccine comprising a polysaccharide antigen conjugated to a carrier protein
SI1082965T1 (sl) 1995-06-23 2009-08-31 Glaxosmithkline Biolog Sa Sestavek cepiva, ki vsebuje antigen konjugata polisaharida, adsorbiranega na aluminijevem fosfatu
DE19543770C2 (de) 1995-11-24 1998-11-05 Metallgesellschaft Ag Vorrichtung zur Messung von kondensierter Feuchtigkeit in Vorrichtungen und/oder Rohrleitungen der chemischen Technik und deren Verwendung
WO1997029773A1 (fr) * 1996-02-13 1997-08-21 The Nisshin Oil Mills, Ltd. Emulsion et poudre renfermant un vaccin et destinees a une administration orale, et procede de production associe
JP2000511411A (ja) 1996-05-01 2000-09-05 ザ ロックフェラー ユニヴァーシティ 抗―肺炎球菌ワクチン用のコリン結合タンパク質
US5766520A (en) * 1996-07-15 1998-06-16 Universal Preservation Technologies, Inc. Preservation by foam formation
EP1015826A2 (en) * 1996-05-29 2000-07-05 Universal Preservation Technologies, Inc. Long-term shelf preservation by vitrification
RO120819B1 (ro) * 1996-07-02 2006-08-30 Connaught Laboratories Limited Vaccinuri dtp multivalente
FR2751000B1 (fr) 1996-07-12 1998-10-30 Inst Nat Sante Rech Med Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques
DE19630390A1 (de) 1996-07-26 1998-01-29 Chiron Behring Gmbh & Co Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
AU5194598A (en) 1996-10-31 1998-05-22 Human Genome Sciences, Inc. (streptococcus pneumoniae) antigens and vaccines
US6051238A (en) * 1996-12-20 2000-04-18 Merck & Co., Inc. Stabilizers for lyophilized mumps vaccines
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
SE511963C2 (sv) 1997-04-23 1999-12-20 Ericsson Telefon Ab L M Anordning och förfarande för bestämning av linjespänning i en abonnentlinjekrets
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
HUP0002475A3 (en) 1997-07-21 2002-01-28 Baxter Healthcare S A Wallisel Modified immunogenic pneumolysin compositions as vaccines
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
EP1028750B1 (en) * 1997-09-15 2006-02-01 Sanofi Pasteur MSD Method for preparing multivalent vaccines
AU762606B2 (en) 1997-11-21 2003-06-26 Genset S.A. Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
DE69735600T2 (de) * 1997-11-26 2007-01-25 Universal Preservation Technologies, Inc., San Diego Konservierung empfindlicher biologischer proben durch verglasung
EP2228384A1 (en) 1997-11-28 2010-09-15 Merck Serono Biodevelopment Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
CA2317815A1 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
ATE461709T1 (de) 1998-04-07 2010-04-15 Medimmune Llc Choline-bindende proteine derivate aus pneumokoken als impfstoff
GB9807721D0 (en) 1998-04-08 1998-06-10 Chiron Spa Antigen
PT1093517E (pt) 1998-05-01 2008-06-12 Novartis Vaccines & Diagnostic Antigénios e composições da neisseria msningitidis
US6306345B1 (en) 1998-05-06 2001-10-23 Universal Preservation Technologies, Inc. Industrial scale barrier technology for preservation of sensitive biological materials at ambient temperatures
MXPA01003557A (es) 1998-10-09 2004-04-05 Chiron Corp Secuencias genomicas de neisseria y metodos para su uso.
CA2347849C (en) 1998-10-22 2013-06-25 The University Of Montana Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof
EP1133572A4 (en) 1998-11-12 2005-06-15 Univ California GENOMIC SEQUENCE OF CHLAMYDIA PNEUMONIAE
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
HU229968B1 (hu) 1999-03-19 2015-03-30 Smithkline Beecham Biologicals S.A Sztreptokokkusz oltóanyag
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
JP4948731B2 (ja) 1999-12-02 2012-06-06 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 凍結乾燥の際に生物学的分子を安定化するための組成物および方法
EP2281570A3 (en) 2000-01-17 2012-05-09 Novartis Vaccines and Diagnostics S.r.l. Outer membrane vesicle (OMV) vaccine comprising n. meningitidis serogroup B outer membrane proteins
PT2270030E (pt) 2000-02-28 2012-07-24 Novartis Vaccines & Diagnostic Expressão heteróloga de proteínas de neisseria
IL153506A0 (en) * 2000-06-29 2003-07-06 Glaxosmithkline Biolog Sa Multivalent vaccine composition
EP1297005B1 (en) 2000-07-03 2009-08-26 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia pneumoniae
KR100385711B1 (ko) * 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
MXPA03003690A (es) 2000-10-27 2004-05-05 Chiron Spa Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
WO2003009869A1 (en) 2001-07-26 2003-02-06 Chiron Srl. Vaccines comprising aluminium adjuvants and histidine
CA2482448C (en) * 2002-04-11 2014-07-08 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
TWI332843B (en) 2002-11-01 2010-11-11 Glaxosmithkline Biolog Sa Immunogenic composition
GB0409795D0 (en) 2004-04-30 2004-06-09 Glaxosmithkline Biolog Sa Drying method
US9473463B2 (en) 2014-07-29 2016-10-18 Combined Conditional Access Development & Support, LLC Control word and associated entitlement control message caching and reuse

Also Published As

Publication number Publication date
AU2003278166A1 (en) 2004-05-25
ES2649048T3 (es) 2018-01-09
KR101058978B1 (ko) 2011-08-23
ES2645924T3 (es) 2017-12-11
MXPA05004528A (es) 2005-07-26
MXPA05004675A (es) 2005-06-08
MA27551A1 (fr) 2005-10-03
CA2503946A1 (en) 2004-05-13
NO20051998D0 (no) 2005-04-25
ES2280809T3 (es) 2007-09-16
PL377170A1 (pl) 2006-01-23
TWI332843B (en) 2010-11-11
IS7805A (is) 2005-04-18
KR20050084626A (ko) 2005-08-26
CA2503946C (en) 2016-08-16
US20110159038A1 (en) 2011-06-30
DK1556477T3 (en) 2017-10-23
NO20052010D0 (no) 2005-04-25
MA27644A1 (fr) 2005-12-01
EP2395073A3 (en) 2012-01-25
BR0315767A (pt) 2005-09-06
PT2395073T (pt) 2017-11-24
KR101130948B1 (ko) 2012-03-30
DE60311526D1 (de) 2007-03-15
NO342741B1 (no) 2018-08-06
SI1556477T1 (sl) 2017-12-29
WO2004039399A1 (en) 2004-05-13
IS3028B (is) 2021-05-15
AR041881A1 (es) 2005-06-01
HK1085380A1 (en) 2006-08-25
AU2003287980A1 (en) 2004-05-25
JP4579156B2 (ja) 2010-11-10
US8449865B2 (en) 2013-05-28
EP2395073B1 (en) 2017-09-06
DE60311526T2 (de) 2007-10-31
US8409587B2 (en) 2013-04-02
PT1556477T (pt) 2017-11-14
LT1556477T (lt) 2017-10-25
US20060127414A1 (en) 2006-06-15
NZ539613A (en) 2008-09-26
IL168054A (en) 2011-06-30
AR041880A1 (es) 2005-06-01
PL376950A1 (pl) 2006-01-09
WO2004039417A2 (en) 2004-05-13
EP2395073A2 (en) 2011-12-14
NO20180874A1 (no) 2005-06-24
EP1575612A1 (en) 2005-09-21
NO20052010L (no) 2005-06-24
KR20050075766A (ko) 2005-07-21
EP1575612B1 (en) 2007-01-24
US7927858B2 (en) 2011-04-19
CY1119504T1 (el) 2018-03-07
TW200501981A (en) 2005-01-16
CA2503871A1 (en) 2004-05-13
LT2395073T (lt) 2017-11-10
MY145693A (en) 2012-03-30
PL215237B1 (pl) 2013-11-29
AU2003278166B2 (en) 2009-01-29
NO344759B1 (no) 2020-04-14
DK2395073T3 (en) 2017-10-23
ATE352316T1 (de) 2007-02-15
MX343419B (es) 2016-11-04
JP2006512406A (ja) 2006-04-13
TW200501980A (en) 2005-01-16
WO2004039417A3 (en) 2004-12-16
CA2503871C (en) 2012-12-11
AU2003287980B2 (en) 2009-06-25
IL168052A0 (en) 2011-08-01
SI2395073T1 (sl) 2017-12-29
MY132859A (en) 2007-10-31
CY1119362T1 (el) 2018-03-07
NZ539706A (en) 2008-03-28
JP2006504801A (ja) 2006-02-09
HUE034801T2 (en) 2018-02-28
IL168052A (en) 2015-03-31
US20060127415A1 (en) 2006-06-15
EP1556477B1 (en) 2017-08-09
EP1556477A2 (en) 2005-07-27
PL213647B1 (pl) 2013-04-30
IS7806A (is) 2005-04-18

Similar Documents

Publication Publication Date Title
NO20051998L (no) Torke prosess
AR125151A2 (es) Composición estabilizadora de almacenamiento en seco para materiales biológicos
NO990158D0 (no) Konservering ved skumdannelse
WO2005105978A3 (en) Drying process for preserving an active agent as a highly viscous liquid
WO1998002240B1 (en) Preservation by foam formation
CN101971796B (zh) 无蛋白非程序细胞冻存液
BRPI0314458B1 (pt) método para a redução do teor de acrilamida em alimentos termicamente processados e respectivo produto alimentício
JP2010509562A5 (no)
Ó’Fágáin et al. Storage and lyophilization of pure proteins
Kumar Lyophilization: An important formulation technique
BR102014025999B1 (pt) método para a preparação de um extrato seco
PL423396A1 (pl) Sposób wytwarzania uwęglonego adsorbentu haloizytowego do adsorpcji paracetamolu z fazy wodnej
CN113074519B (zh) 一种高效去除门冬胰岛素中残留有机溶剂的方法
Patel et al. Freeze drying of high aspect ratio structures
CN107469379A (zh) 一种样品中残留水溶性有机溶剂的去除方法
CN206507214U (zh) 真空干燥萃取系统
Taragano et al. Calorimetric studies on dry pectinlyase preparations: impact of glass transition on inactivation kinetics
Dhangar et al. Evaporation A unit operation in pharmaceutical industry
TWI623270B (zh) 真空乾燥萃取系統及其操作方法
JP3937019B2 (ja) 微生物保存用分散媒及び微生物保存用容器
de Oliveira et al. PRODUCTION OF DRIED BANANA OF THE CULTIVAR ‘D’ANGOLA’BY THE OSMO-CONVECTIVE METHOD
BR0315733A (pt) Método para conservar um agente ativo, liquido altamente viscoso, composição imunogênica ou vacina, método para fabricar uma vacina, e, kit
Moonchai et al. Effect of Variables on Honey Dehydration
Pandhare et al. REVIEW ON: LYOPHILIZATION PROCESS OF PHARMACEUTICALS.
Adiya et al. Vacuum Contact Drying of Pharmaceutical Powders with and without agitation: A Comparison

Legal Events

Date Code Title Description
MK1K Patent expired